News & Insights

In a recent interview with the leading German real estate industry magazine immobilienmanager , Martin Eberhardt, Managing Partner of HELIX alpha, discusses the company’s strategy and its vision for building a pan-European Life Science Real Estate platform. The conversation highlights the importance of local market expertise, the growing relevance of life science ecosystems and the opportunities arising from the ongoing transformation of the real estate industry. Read the ful

December 2026 I Corporate News We are truly excited to share a major milestone for HELIX alpha. We have appointed an exceptional, interdisciplinary Advisory Board - an important step in strengthening our company’s development and our ability to navigate the young and complex asset class of life science real estate. We welcome four outstanding experts as voting members of our Investment & Risk Committee: Prof. Dr. Thomas Glatte – Chair of the board, real estate leader with t

HELIX alpha is partner of the event "Life Science Immobilien" with Heuer Dialog

November 2025 | Company News HELIX alpha announces the launch of its European investment platform focused on Life Science Real Estate. The company combines expertise in real estate, capital markets and life sciences to provide institutional investors with access to a highly specialized asset class. Download the full press release:

In Zeiten der Unsicherheit sind Anleger auf der Suche nach Anlageklassen, die Substanz besitzen und zukunftsträchtig sind. Martin Eberhardt FRICS behandelt in seinem Beitrag „Life Science Real Assets – Strategischer Stabilitätsanker für institutionelle Investoren“ für die Property Post dieses Thema. Im Mittelpunkt stehen hochspezialisierte Immobilien wie Labore, Forschungszentren oder Produktionsstätten, die von Megatrends wie demografischem Wandel, personalisierter Medizi

Throughout his career, Martin Eberhardt has been fortunate to pioneer emerging real estate asset classes – from Student Housing, Communication Infrastructure to Car Parks – identifying their potential long before they became mainstream. Today, he sees the same compelling dynamics in Life Sciences Real Estate (LSRE). In his latest article, he outlines why LSRE should no longer be considered a niche but a strategic portfolio component: Resilient returns in volatile, challenging